Twist Bioscience Corp reports results for the quarter ended June 30 - Earnings Summary
Twist Bioscience Corp reports results for the quarter ended June 30 - Earnings Summary
Twist Bioscience Corp TWST.OQ reported a quarterly adjusted loss of 56 cents per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -47 cents. The mean expectation of ten analysts for the quarter was for a loss of 49 cents per share. Wall Street expected results to range from -52 cents to -45 cents per share.
Revenue rose 23.2% to $118.38 million from a year ago; analysts expected $114.49 million.
Twist Bioscience Corp's reported EPS for the quarter was a loss of 56 cents.
The company reported a quarterly loss of $35.05 million.
Twist Bioscience Corp shares had fallen by 11.0% this quarter and gained 188.6% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 9.7% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for Twist Bioscience Corp is $95.00, about 3.6% above its last closing price of $91.55
This summary was machine generated from LSEG data August 3 at 02:06 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.49 | -0.56 | Missed |
Mar. 31 2026 | -0.48 | -0.59 | Missed |
Dec. 31 2025 | -0.43 | -0.50 | Missed |
Sep. 30 2025 | -0.43 | -0.45 | Missed |